About
BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support three marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have ov
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 1,074 investors are based in Shanghai, Shanghai, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Shanghai, China
Contact Information
Find more investors like BioRay
Search Investors